Clarisa Blattner: What Labs Can Learn from Reimbursement Variability Across Health Plans
An argument is made for clinical laboratories to use payer rate transparency as a cornerstone of commercial intelligence
Author Information
Clarisa Blattner, CCS, CPC
Clarisa Blattner, CCS, CPC, is senior director of reimbursement strategy and industry affairs at XiFin, where she serves as a subject matter expert in revenue cycle management (RCM), focusing on achieving operational efficiencies and maximizing revenue. With over 20 years of experience in the healthcare sector, Blattner has an extensive background in RCM, particularly within the clinical lab industry. Previously at XiFin, she oversaw billing and reimbursement operations for the outsourced billing department, cultivating and directing a large team of revenue cycle personnel to service independent labs in multiple specialties. She has served in leadership roles at organizations such as US Labs, Clarient, and MDxHealth.
Posts by the Author
Beyond Prior Authorization Reform: The Next Measure of Administrative Simplification
Clinical labs can serve as early observers of this transition
Clarisa Blattner: MACs Refresh Medicare DOS Guidance
Why clinical laboratories should pay attention even though date-of-service rules haven’t changed
Clarisa Blattner: Could Medicare LCD Policy Be Poised for Reform?
Details behind the proposed Timely Access to Coverage Decisions Act
Clarisa Blattner: The MRD Testing Reimbursement Challenge
Why operational readiness is becoming just as important as clinical innovation
Clarisa Blattner: PAMA Reporting 2026—5 Strategic Priorities Clinical Laboratories Can’t Afford to Miss
Validating applicable laboratory status is an important first step in reporting
